Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 344

Ban on gain-of-function studies ends

The debate is focused on a subset of gain-of-function studies that manipulate deadly viruses to increase their transmissibility or virulence. “This is what happens to viruses in the wild”, explains Carrie Wolinetz, head of the NIH Office of Science Policy. “Gain-of-function experiments allow us to understand how pandemic viruses evolve, so that we can make predictions, develop countermeasures, and do disease surveillance”. Although none of the widely publicised mishaps of 2014 involved such work, the NIH decided to suspend funding for gain-of-function studies involving influenza, MERS-CoV, and SARS-CoV.

The US moratorium on gain-of-function experiments has been rescinded, but scientists are split over the benefits—and risks—of such studies. Talha Burki reports.

On Dec 19, 2017, the US National Institutes of Health (NIH) announced that they would resume funding gain-of-function experiments involving influenza, Middle East respiratory syndrome coronavirus, and severe acute respiratory syndrome coronavirus. A moratorium had been in place since October, 2014. At the time, the NIH had stated that the moratorium “will be effective until a robust and broad deliberative process is completed that results in the adoption of a new US Government gain-of-function research policy”. This process has now concluded. It was spearheaded by the National Science Advisory Board for Biosecurity (NSABB) and led to the development of a new framework for assessing funding decisions for research involving pathogens with enhanced pandemic potential. The release of the framework by the Department of Health and Human Services (HHS), of which NIH is part, signalled the end of the funding pause.

The situation has its roots in 2011, when the NSABB suppressed two studies involving H5N1 viruses that had been modified to allow airborne transmission from ferret to ferret. They worried that malign actors could replicate the work to deliberately cause an outbreak in human beings. After much debate, the studies were published in full in 2012. HHS subsequently issued guidelines for funding decisions on experiments likely to result in highly pathogenic H5N1 viruses transmissible from mammal to mammal via respiratory droplets. The guidelines were later expanded to include H7N9 viruses.

Help NYC artist Maria Alekseev

Maria became the very first COVID-19 patient to use Stem Cell Neurotherapy for COVID-19. In about 5 days, she will began to feel the healing effects of generating new lung cells which will eliminate her breathing problems.

We repurposed some tools from the Stem Cell Therapy for Cancer/Brain Tumor. Those tools are T-Cells, B-Cells, and Natural Killer Cells. Instead of programming those cancer killing cells to attack cancer cells, we have programmed them to seek out, identify, attack, and destroy all the Coronavirus cells in the entire body.

Stem Cell Neurotherapy sends therapeutic messages, e.g., “your stem cells are transforming into new cells for the lungs, liver, and kidneys” to the DNA inside the nucleus of stem cells. Inside the nucleus, the DNA receives the message and transmits it to the RNA, which translates the message into genetic code.

The genes inside the stem cells transmit the coded message to the proteins, which are converted by the mitochondria into ATP, which provides the energy for the coded message to transform the stem cells into a new set of lung cells, as well as new cells for the kidneys and liver.

These new cells in the lungs, kidneys, and liver will replace the cells that were infected by the COVID-19 virus. This results in the elimination of the coughing, fever, headaches, diarrhea, and breathing problems.

I’m reaching out with great humility, like a great many people are these days, to see if anyone has it within their means to help me directly or indirectly. As an artist, teaching in the New York City school system mostly working children in ESL and Special Needs, my work is seasonal and I am an independent contractor. This means no benefits even after close to 10 years in the same “job”, and from a complicated financial situation with my husband, neither of us has health insurance, everything is out of pocket for us. I’m not eligible for unemployment due to being a contractor. My gigs for this semester totaling almost $5000 for NYC schools just evaporated in the blink of an eye, but would have covered the cost my everyday healthcare/rent/etc until September. Things like medicines and supplements, healthy food that help control my Essential Tremor(neurological disease) and anxiety and vision care that allow me to function as an artist and make a meager living will be eliminated if we want to keep a roof over our heads. And now due to restrictions in NYC, my husband could be out of work by tomorrow(also contract work with no-unemployment benefits). If you can donate even the smallest token it would be of great help. Any amount would help me to weather the next several months of the NYC lockdown. If you feel strange donating cash, please take a look at the reproductions of my art, or maybe even buy a gift card for someone that might like my art here: opticvoid.com

Continue reading “Help NYC artist Maria Alekseev” | >

The Second Study on Vitamin D and COVID-19 Is Now Out

The first study on vitamin D and COVID-19 was released as a preprint on April 23, and a second study was released as a preprint on April 26. Here’s what we can learn from the second study. The first study, which I reported on a few days ago, focused on disease severity, while the second one, which I’m reporting on here, focused on mortality.

The Results

The electronic health records of 780 laboratory-confirmed COVID-19 cases from the government hospitals of Indonesia between March 2 and April 24 was searched for data on vitamin D status prior to admission, age, sex, preexisting conditions, and mortality. Vitamin D status was classified as normal (≥30 ng/mL), insufficient (21−29 ng/mL), or deficient (≤20 ng/mL).

Live Science’s Weekly Coronavirus update with health reporter, Nicoletta Lanese

We are going over the latest news, as well as any breakthrough findings on the virus. In today’s updates, we’ll discuss Remdesivir, elevated risk of severe infection in men, COVID toes, UK vaccine trial as well as answer your questions from the comments below.

Numbers update
:04 Remdesivir
:10 Gender differences with COVID-19
:14 Covid Toes
:16 Rare inflammatory syndrome in children.
:18 UK Vaccine trial
:19 Pete the Cat
:20 How Are people carriers without symptoms?
:25 Could COVID-19 vaccine lead to common cold vaccine?
:27 How to clean groceries after shopping?
:29 Do postmenopausal women suffer infections as bad as men?
:32 How are people in the hospital being treated for COVID-19?
:34 How successful is plasma therapy?
:36 How is COVID-19 data being collected?
:39 Can you get reinfected after recovering from the virus?
:42 How long does immunity last (if immune at all)?
:45 Can the virus enter the body thru the eyes/ears.

Manufacturing Platform Developed for Large-Scale Production of COVID-19 Vaccine Candidate

MilliporeSigma and The Jenner Institute report that the Institute has begun preparations for the large-scale production of its COVID-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a critical step in quickly and safely delivering it from the lab to patients, according to Udit Batra, CEO, MilliporeSigma.

“We have brought the future of vaccine manufacturing to the present,” said Batra. “This is an important step in treating COVID-19 and other diseases that impact global public health. This work marks a milestone in the vaccine manufacturing development journey, as clinical testing continues to advance.”

Tapping into MilliporeSigma’s previous work provided a head start for plans to scale up the manufacture of Jenner’s COVID-19 vaccine candidate, added Batra. Developing the manufacturing process itself would normally take at least six months to a year, but in just two months’ time, MilliporeSigma supported the Jenner team and their collaborators to evaluate the existing manufacturing platform for use with the new vaccine candidate, and improved critical process steps, he continued.

Study Finds Eating More “Nattō” Reduces Risk of Mortality

The study of both fermented and non-fermented soy products was based on the results of research carried out on approximately 90,000 men and women between the ages of 45 and 74 over a period of 15 years. The team calculated intake quantities for all soy products and fermented products only through a dietary survey and examined the relationship with mortality in five similarly sized groups.

Findings from a scientific study help support the long-held belief that fermented soy products like nattō are good for one’s health.

Study finds high blood pressure medications safe for patients with COVID-19 disease

This is very surreal. A study was done to assess the safety of common drugs, and COVID, and whether taking them leads to severe symptoms. There has been concern as these drugs increase ACE2 receptors coronavirus binds to. So someone had the bright idea of going through over 12,000 digital patients records to come up with the conclusion the drugs are safe to take and they do not cause worse symptoms. No animal studies, no clinical trials, and this was actually published.

“For the study, the researchers identified patients in the NYU Langone Health electronic health record with COVID-19 test results. For each identified patient with COVID-19 test results, the team discretely extracted medical history needed for the analysis, which compared treated and untreated patients.”

First you do a mouse study at least to review how coronavirus behaves in mice who are given the drugs, and compare it to mice not given the drugs. If science has been reduced to just going over records and coming to a conclusion, with no experimentation I have officially lost my mind.

Despite concerns expressed by some experts, common high blood pressure drugs did not increase the risk of contracting COVID-19 — or of developing severe disease — in a study of 12,594 patients.

Published online May 1 in the New England Journal of Medicine, the study was launched in response to a March 17 joint statement issued by the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America. It urgently called for research to answer a question raised by past studies: do high blood pressure (antihypertensive) drugs worsen COVID-19 patient outcomes?

Led by researchers from NYU Grossman School of Medicine, the study found no links between treatment with four drug classes — angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, or calcium channel blockers — and increased likelihood of a positive test for COVID-19.

Continue reading “Study finds high blood pressure medications safe for patients with COVID-19 disease” | >

Cytokine storms and T cell counts may offer clues on how to treat COVID-19

Cytokine storms may affect the severity of COVID-19 cases by lowering T cell counts, according to a new study published in Frontiers in Immunology. Researchers studying coronavirus cases in China found that sick patients had a significantly low number of T cells, a type of white blood cell that plays a crucial role in immune response, and that T cell counts were negatively correlated with case severity.

Interestingly, they also found a high concentration of cytokines, a protein that normally helps fight off infection. Too many cytokines can trigger an excessive inflammatory response known as a cytokine storm, which causes the proteins to attack . The study suggests that coronavirus does not attack T cells directly, but rather triggers the cytokine release, which then drives the depletion and exhaustion of T cells.

The findings offer clues on how to target treatment for COVID-19, which has become a worldwide pandemic and a widespread threat to human health in the past few months. “We should pay more attention to T cell counts and their function, rather than respiratory function of patients,” says author Dr. Yongwen Chen of Third Military Medical University in China, adding that “more urgent, may be required in patients with low T lymphocyte counts.”

/* */